What are the current Indian tuberculosis guidelines for diagnosis and treatment of drug‑sensitive, multidrug‑resistant, and extensively drug‑resistant TB?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Latest TB Guidelines for India

India's National TB Elimination Program (NTEP) updated its Programmatic Management of Drug-Resistant TB (PMDT) guidelines in March 2021, adopting shorter all-oral bedaquiline-based regimens and phasing out injectable agents for drug-resistant TB, while maintaining the standard 6-month four-drug regimen (2HRZE/4HR) for drug-susceptible cases. 1

Drug-Susceptible TB Treatment

Standard Regimen for Adults

  • The recommended treatment is a 6-month course: 2 months of isoniazid (H), rifampin (R), pyrazinamide (Z), and ethambutol (E), followed by 4 months of isoniazid and rifampin. 2, 3
  • Daily administration is strongly preferred over intermittent dosing, with directly observed therapy (DOT) 5-7 days per week. 4, 3
  • India transitioned to daily dosing regimens in 2015, moving away from intermittent therapy. 5

Weight-Based Dosing (for ~70 kg adult)

  • Isoniazid: 300 mg daily (5 mg/kg, maximum 300 mg) 2
  • Rifampin: 600 mg daily (10 mg/kg, maximum 600 mg) 2
  • Pyrazinamide: 2000 mg daily (15-30 mg/kg range, capped at 2000 mg) 2
  • Ethambutol: 1200 mg daily (15-25 mg/kg; for 56-75 kg weight band) 2
  • Pyridoxine (vitamin B6): 25-50 mg daily with isoniazid to prevent peripheral neuropathy 2, 3

Pediatric Regimen (Ages 3 months to 16 years)

  • For children with non-severe TB (no cavitation, no MDR/RR-TB suspicion), a 4-month regimen (2HRZ(E)/2HR) is now recommended instead of the traditional 6-month course. This represents a major advance in reducing treatment burden. 4, 3

Drug-Resistant TB Treatment

Diagnostic Advances in India

  • India's 2021 PMDT guidelines incorporate newer diagnostics including TrueNat, Xpert MTB/XDR, and next-generation sequencing for resistance detection to bedaquiline and delamanid. 1
  • Molecular testing for fluoroquinolone resistance is essential before initiating shorter regimens. 6

Rifampin-Resistant, Fluoroquinolone-Susceptible TB (MDR/RR-TB)

  • For adolescents ≥14 years and adults, use the 6-month BPaLM regimen (bedaquiline + pretomanid + linezolid + moxifloxacin) instead of 15-month or longer regimens. 4, 3

BPaLM Dosing:

  • Bedaquiline: 400 mg daily × 2 weeks, then 200 mg three times weekly × 24 weeks 4, 3
  • Pretomanid: 200 mg daily × 26 weeks 4, 3
  • Linezolid: 600 mg daily × 26 weeks 4, 3
  • Moxifloxacin: 400 mg daily × 26 weeks 4, 3
  • All medications taken with food, avoiding milk/antacids; DOT 5 of 7 days per week 4, 3

Rifampin-Resistant TB with Fluoroquinolone Resistance or Intolerance

  • Use the 6-month BPaL regimen (bedaquiline + pretomanid + linezolid, without moxifloxacin) for patients with ≤1 month prior exposure to bedaquiline or linezolid. This achieves 90-100% treatment success. 4, 3

Longer MDR-TB Regimens (When BPaL/BPaLM Not Suitable)

  • Group A agents (levofloxacin/moxifloxacin, bedaquiline, linezolid) should form the backbone: Use all three Group A agents plus at least one Group B agent to ensure ≥4 effective drugs initially. 6
  • Bedaquiline and linezolid are now strongly recommended (upgraded from conditional recommendations) for longer MDR-TB regimens in adults ≥18 years. 6
  • Kanamycin and capreomycin are NOT to be included in MDR/RR-TB treatment—India's 2021 guidelines phase out injectables. 6, 1

Isoniazid-Resistant, Rifampin-Susceptible TB

  • Use rifampin, ethambutol, pyrazinamide, and levofloxacin for 6 months. 6
  • Do NOT add streptomycin or other injectable agents. 6

Key Indian Context Considerations

Updated Definitions (2021 PMDT Guidelines)

  • India updated definitions for pre-XDR TB, XDR TB, culture conversion, and treatment default in the March 2021 guidelines. 1

Major Challenges in India

  • India accounts for 27% of global DR-TB cases, making control efforts critical. 7
  • Peripheral and resource-limited areas face substantial challenges in DR-TB care access. 7
  • Late diagnosis and inadequate access to effective treatment worsen outcomes. 8
  • The COVID-19 pandemic disrupted TB control achievements, with lockdowns impairing case detection and treatment continuity. 9

Monitoring Requirements

  • Baseline testing: Visual acuity (Snellen), color discrimination (Ishihara), liver function (AST, ALT, bilirubin, alkaline phosphatase), serum creatinine, and platelet count before starting treatment. 2
  • Monthly monitoring: Query patients about visual disturbances while on ethambutol. 2

Special Situations

Tuberculous Pericarditis

  • Use the standard 6-month four-drug anti-TB regimen (not the 4-month pediatric regimen), as pericardial TB is a severe manifestation. 10
  • Add adjunctive corticosteroids: Prednisone 1-2 mg/kg/day × 5-7 days, then taper over 6-8 weeks. 10
  • Pericardiocentesis is indicated for tamponade or symptomatic large effusions not improving with medical therapy. 10
  • Pericardiectomy is indicated if clinical status fails to improve or worsens after 4-8 weeks of treatment, or if chronic constrictive pericarditis develops. 10

TB-Endemic Region Considerations

  • In TB-endemic areas like India, empiric anti-TB chemotherapy is recommended for exudative pericardial effusions after excluding other causes. 10

References

2
Guideline

Intensive‑Phase Dosing Guidelines for Drug‑Susceptible Pulmonary Tuberculosis in Adults

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

3
Guideline

Updated 2025 ATS/CDC/ERS/IDSA Tuberculosis Treatment Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

5
Research

Transitioning to daily treatment for drug-sensitive TB in India.

The Indian journal of tuberculosis, 2015

10
Guideline

Management of Tuberculous Pericarditis (Evidence‑Based Recommendations)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What are the current Indian guidelines for tuberculosis treatment, including recommended regimens for drug‑susceptible and multidrug‑resistant TB?
What is the most appropriate treatment regimen for a 35-year-old Indian man presenting with three months of lethargy, weight loss, and headache, a history of tuberculosis exposure, normal neurological and ophthalmologic examinations, and a positive polymerase chain reaction for Mycobacterium tuberculosis?
How can I determine the likelihood of drug-resistant tuberculosis in a 5-year-old child?
What is the recommended all‑oral treatment regimen, including drug selection, dosing, duration, and monitoring, for adults with multidrug‑resistant pulmonary tuberculosis?
What is the typical duration that latent Mycobacterium tuberculosis infection can persist, and how long does active tuberculosis usually take to develop symptoms?
How should airway management be performed in an ICU patient, including rapid sequence intubation technique, drug dosing, tube confirmation, ventilation settings, sedation, and rescue options?
What should I do for a blood pressure of 140/110 mm Hg, and could it be caused by acidity, caffeine, or heart disease?
What does Kussmaul respiration indicate and what immediate investigations and management should be performed?
Which FDA‑approved liquid biopsy assays can be used for diagnosis, treatment selection, and prognosis?
Why should a CT urography be obtained before a cystoscopic transurethral resection of bladder tumor (TURBT)?
What are the indications, recommended settings, and contraindications for using Adaptive Servo‑Ventilation (ASV) in patients with central or complex sleep apnea?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.